Fosun Pharma has cut back its offer for Gland Pharma just enough to circumvent the Indian government’s scrutiny.
China’s 3SBio, in a joint venture with CPE Funds, seeks to buy Canadian CDMO Therapure Biomanufacturing for $290 million pending shareholder approval.
Did Daiichi Sankyo receive a buyout bid from AstraZeneca last year? According to the Japanese drugmaker, no.
India-based Alembic Pharmaceuticals is selling its formulation manufacturing plant in Baddi to Scott Edil Pharmacia for an undisclosed amount.
Shareholders of India’s Gland Pharma, an injectables manufacturer, are said to be considering selling a 74% stake to China’s Fosun Pharma as a hedge against…
Fosun Pharma and Shanghai Pharma are bidding for a stake in U.S. drugmaker Arbor Pharma.
WuXi's small molecule CDMO STA is adding a drug development services operation as it builds itself into an end-to-end CDMO.
It's the second time in two years that rumors about Fosun Chairman Guo Guangchang's whereabouts stirred the market.
Bristol-Myers Squibb will unload an API plant in Ireland to a South Korean company with large aspirations in contract manufacturing.
Bharat Biotech has initiated a phase 1 trial of its Chikungunya vaccine, while Themis started a phase 2 of its own candidate.